Core Insights - ImmunityBio Inc. plans to submit additional information to the FDA regarding its supplemental biologics license application for Anktiva in treating papillary non-muscle invasive bladder cancer (NMIBC) within 30 days [1][2] - The stock has seen significant trading activity, with a session volume of 178.91 million compared to an average of 15.9 million [1] FDA Interaction - The FDA provided feedback during discussions on Anktiva in combination with Bacillus Calmette-Guérin for patients with BCG-unresponsive papillary NMIBC, which supports a potential resubmission of the sBLA filed initially in 2025 without requiring a new clinical trial [2] Clinical Results - Updated clinical results presented included over five years of follow-up data, showing disease-specific survival of approximately 96% at 36 months and cystectomy avoidance rates of 92% at one year and 82% at three years [3][4] - The safety profile of Anktiva is consistent with its currently approved indication in carcinoma in situ [4] Trial Data - The QUILT-3.032 Phase 2/3 trial, which enrolled 80 patients with high-grade, papillary-only BCG-unresponsive NMIBC, met its primary endpoint with a 12-month disease-free survival rate of 58.2% and progression-free survival rates of 94.9% at 12 months and 83.1% at 36 months [5] Market Performance - Anktiva is already approved in the U.S. and several international markets for BCG-unresponsive NMIBC with carcinoma in situ [6] - Preliminary net product revenue for Anktiva reached approximately $113 million for fiscal 2025, reflecting a 700% year-over-year increase [7] - For Q4 2025, revenue was about $38.3 million, marking a 20% quarter-over-quarter increase and a 431% year-over-year increase [7] Analyst Ratings - Piper Sandler maintains an Overweight rating for ImmunityBio and raises the price forecast from $5 to $7, while D. Boral Capital maintains a Buy rating with a price forecast of $24 [8] - ImmunityBio shares were up 20.44% at $6.64, reaching a new 52-week high [8]

Core Insights - ImmunityBio had a remarkable performance in 2025, setting a strong foundation for 2026 [2] Group 1: Company Achievements - The company received approval for its bladder cancer treatment in 2024, which was a significant milestone [3] - In January 2026, ImmunityBio received its J-Code, enabling the commercial team to effectively market their product [4]

Core Viewpoint - CG Oncology is focused on developing a bladder-sparing therapeutic for bladder cancer patients, targeting a market of approximately 150,000 patients annually in the U.S. [2] Company Overview - The incidence of bladder cancer in the U.S. is about 85,000 patients per year, with a prevalence exceeding 700,000 patients [3] - 75% of bladder cancer patients are classified as non-muscle invasive, which is characterized by frequent recurrences that can lead to progression and metastatic disease [3] Strategic Focus - CG Oncology is concentrating on the non-muscle invasive bladder cancer segment, specifically targeting intermediate risk and high-risk populations [4] - The company has invested in two pivotal Phase III trials, with one expected to read out results in the first half of this year [4]

Core Insights - The FDA has provided written feedback supporting the registrational development pathway for Relmada Therapeutics' NDV-01 in treating high-grade BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) and intermediate-risk NMIBC in the adjuvant setting [1][2][3] Group 1: FDA Feedback and Clinical Trials - The FDA indicated that a single-arm, open-label clinical trial for NDV-01 in high-grade, BCG-unresponsive NMIBC is an appropriate registrational approach, facilitating a potential NDA submission [2] - The FDA also supported a planned single registrational study in intermediate-risk NMIBC, which will follow an open-label, randomized-to-observation design [3] - Both registrational trials are anticipated to initiate in the first half of 2026 [1][3] Group 2: Study Designs and Objectives - The pivotal Phase 3 study for high-grade NMIBC will evaluate the drug's efficacy based on FDA guidance regarding study population, endpoint selection, and evaluation methodology [5][8] - The primary endpoint for the intermediate-risk NMIBC study will be the complete response (CR) rate, with a key secondary endpoint of duration of response (DOR) [6][7] - Assessments for both studies will include cystoscopy, cytology, and biopsy as per protocol [8] Group 3: Product Overview - NDV-01 is a sustained-release, intravesical formulation of gemcitabine and docetaxel, designed for gradual drug release over ten days, enhancing local exposure while minimizing systemic toxicity [9] - The formulation is convenient for in-office administration, requiring less than five minutes and no anesthesia or specialized equipment [9] - NDV-01 is protected by patents until 2038, indicating a long-term competitive advantage [9] Group 4: Market Opportunity - NMIBC accounts for 75-80% of all bladder cancer cases, with a high recurrence rate of 50-80% over five years, highlighting a significant market opportunity [10] - High-grade BCG-unresponsive disease is particularly challenging to treat, with limited bladder-sparing options available [10] - Intermediate-risk NMIBC in the adjuvant setting currently has no approved therapies, positioning NDV-01 as a potential frontline or salvage therapy [10]

Core Insights - Astellas Pharma and Pfizer announced positive topline results from the Phase 3 EV-304 clinical trial for PADCEV in combination with Keytruda, showing significant improvements in event-free survival and overall survival for muscle-invasive bladder cancer patients [1][5][7] Company Insights - Astellas Pharma is focused on advancing treatment options for muscle-invasive bladder cancer, with recent findings reinforcing the potential of PADCEV plus pembrolizumab to improve survival outcomes for a broad patient population [4][5] - Pfizer emphasizes the significance of the EV-304 results, indicating a potential shift in the standard of care for muscle-invasive bladder cancer patients, particularly those ineligible for platinum-based chemotherapy [5][6] Industry Insights - Muscle-invasive bladder cancer is a significant health concern, with nearly half of patients progressing to metastatic disease within three years of diagnosis, highlighting the need for effective treatment options [3][6] - The EV-304 trial results may lead to a new standard of care in bladder cancer treatment, moving away from conventional platinum-based chemotherapy [5][7]

Core Viewpoint - The European Medicines Agency (EMA) has recommended conditional marketing authorization for ImmunityBio's Anktiva in combination with BCG for treating BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) [1][4]. Group 1: Clinical Trial Results - A single-arm clinical trial involving 100 adults showed a complete response rate of 71%, with responses lasting up to 54+ months and an average duration of approximately 27 months [2]. - The complete response rates at 12 months and 24 months were 66% and 42%, respectively [3]. Group 2: Regulatory and Market Context - The conditional marketing authorization is part of an EU regulatory mechanism aimed at providing early access to medicines for unmet medical needs [4]. - Bladder cancer is the fifth-most common cancer and the seventh most frequently diagnosed cancer in men, with an estimated 200,000 new cases expected in 2025 [4]. - Approximately 75% of these patients (150,000) will have NMIBC, which is the most common form of bladder cancer [5]. Group 3: Next Steps and Market Reaction - ImmunityBio will continue to follow up with trial participants and submit long-term safety and efficacy results to the EMA post-marketing [3]. - Following the EMA's recommendation, the opinion will be forwarded to the European Commission for final approval of EU-wide marketing authorization [6]. - ImmunityBio's shares increased by 2.74% to $2.25 at the time of publication [6].

Core Insights - New data from the Phase 2b SunRISe-1 study indicate that over 95% of patients with high-risk, non-muscle invasive bladder cancer remained progression-free at one year, with more than 92% avoiding bladder removal surgery [1][2][3] Company Overview - Johnson & Johnson is committed to developing innovative treatments for patients with high-risk non-muscle invasive bladder cancer (NMIBC) who have limited options beyond radical cystectomy [2] - The company is focusing on the gemcitabine intravesical system, which has shown promising results in clinical trials for patients unresponsive to Bacillus Calmette-Guérin (BCG) therapy [1][5] Study Details - Cohort 4 of the SunRISe-1 study involved 52 patients with papillary-only, high-risk NMIBC who did not respond to BCG therapy and were ineligible for or declined radical cystectomy [2][5] - The therapy was administered every three weeks for six months, followed by every 12 weeks for up to an additional 18 months [2] Efficacy Results - At a median follow-up of 15.9 months, the one-year disease-free survival (DFS) rate was 74.3%, with progression-free survival (PFS) at 95.6% and overall survival (OS) at 98% [3] - Notably, 92.3% of patients did not undergo radical cystectomy, indicating the treatment's potential to preserve bladder function [3] Safety Profile - The therapy was generally well-tolerated, with 80.8% of patients experiencing low-grade treatment-related side effects, primarily mild urinary symptoms [4] - Serious side effects were uncommon, occurring in 13.5% of patients, and no treatment-related deaths were reported [4] Industry Context - High-risk non-muscle invasive bladder cancer represents a significant challenge in oncology, with traditional treatment options often leading to radical cystectomy, which can severely impact patients' quality of life [2][7] - The ongoing need for effective bladder preservation therapies highlights the importance of studies like SunRISe-1 in addressing unmet medical needs in this patient population [2][7]

Core Insights - The article expresses optimism about enGene Holdings Inc. (ENGN) in the context of bladder cancer research and investment potential [1] Company Analysis - enGene Holdings Inc. is focused on developing therapies for bladder cancer, indicating a specialized niche within the biotech sector [1] - The author has a PhD in biochemistry and extensive experience in analyzing clinical trials and biotech companies, which adds credibility to the insights provided [1] Investment Thesis - The investment thesis for enGene Holdings Inc. is based on its market valuation relative to its potential in the bladder cancer treatment space, suggesting that the company may be undervalued [1]

Core Viewpoint - Relmada Therapeutics has appointed Dr. Raj S. Pruthi as Chief Medical Officer-Urology to advance the development of NDV-01, a novel therapy for non-muscle invasive bladder cancer (NMIBC), with a Phase 3 trial expected to begin in the first half of 2026 [2][4]. Company Overview - Relmada Therapeutics is a clinical-stage biotechnology company focused on innovative therapies for oncology and central nervous system conditions [11]. - The lead program, NDV-01, is designed for the treatment of NMIBC and aims to address significant unmet medical needs in this area [11]. Appointment of Dr. Raj S. Pruthi - Dr. Pruthi brings over 25 years of experience in urologic oncology, clinical trials, and robotic surgery, having previously served as Chief Medical Officer at enGene Holdings Inc. and Global Medical Affairs leader at Johnson and Johnson [3][5]. - His expertise includes developing practice guidelines for NMIBC and executing global clinical studies for bladder cancer treatments [3][6]. NDV-01 Program - NDV-01 is a sustained-release formulation of gemcitabine and docetaxel, designed for intravesical administration, allowing for gradual drug release over 10 days [9]. - The formulation aims to enhance local exposure while minimizing systemic toxicity and is designed for in-office administration in under 10 minutes without the need for anesthesia [9]. - Positive initial Phase 2 data presented at the AUA 2025 indicated impressive response rates and favorable tolerability for NDV-01 [4][10]. Market Opportunity - NMIBC accounts for approximately 75% of all bladder cancer cases, with a high recurrence rate of 50-75% over seven years, indicating a significant market opportunity for effective treatments [10]. - With over 600,000 prevalent cases in the U.S. and limited treatment options, NDV-01 has the potential to serve as a frontline or salvage therapy across multiple NMIBC subtypes [10].

Core Insights - CG Oncology, Inc. announced positive results from the Phase 3 BOND-003 study of cretostimogene grenadenorepvec for high-risk non-muscle invasive bladder cancer (NMIBC) unresponsive to BCG treatment, presented at the 2025 American Urological Association Annual Meeting [1] Study Results - The study reported a 75.5% complete response (CR) rate at any time, with 34 confirmed CRs at 24 months and nine patients pending assessment as of March 14, 2025 [2] - The 12-month and 24-month CR rates were estimated at 50.7% and 42.3%, respectively, with a median duration of response (DOR) of 28 months [3] - 97.3% of patients were free from progression to muscle-invasive disease at 24 months [3] - In Cohort P, patients with BCG-unresponsive Ta/T1 disease without CIS showed an estimated 90.5% high-grade recurrence-free survival at 3 and 9 months [3] Safety Profile - A well-tolerated safety profile was observed, with no Grade 3 or greater treatment-related adverse events (TRAEs) or deaths reported among 110 highly pretreated patients [4] - Patients who experienced TRAEs had a median resolution time of one day, and 97.3% completed all expected treatments, indicating favorable adherence [4][5] Market Reaction - Following the announcement, CGON stock increased by 39.9%, reaching $31.30 [6]